HIV Infections Clinical Trial
Official title:
Strategies for the Prevention of HIV Infection and the Enhancement of Reproductive Health Among Adolescents in Rural Tanzania: MEMA Kwa Vijana Trial
The MEMA kwa Vijana Project is a community randomised trial which aims to assess the impact of a targeted intervention on adolescent sexual and reproductive health in Mwanza Region, Tanzania. The intervention aims to reduce HIV, STD and unwanted pregnancy amongst adolescents by improving reproductive health knowledge and by teaching skills to promote sexual behaviour change, and comprises community mobilisation, skills-based education in primary schools, and youth friendly health services. The evaluation includes a detailed process evaluation, and evaluation of the impact in a cohort of approx. 10,000 adolescents who will be followed for 3 years.
Background: Adolescents are at high risk of adverse reproductive health outcomes, including
HIV, other STIs and unwanted pregnancies. However, there is little empirical evidence to
guide the choice and implementation of effective interventions. We assessed the impact of an
intervention programme on the sexual health of adolescents in rural Tanzania.
Methods: Using data from a prior population-based survey of 9,445 15-19 year olds, 20
communities were stratified and randomly allocated to either receive the new interventions
(Intervention Group) or standard interventions (Comparison Group) during Phase 1 (January
1999-December 2001) of the MEMA kwa Vijana Project. The new intervention programme had four
major components: community activities; teacher-led, peer-assisted sex education in the last
three years of primary school (Years 5-7); training and supervision of health workers to
provide “youth-friendly” STD and family planning services; and peer condom social marketing
for youth (from January 2000). The pre-defined primary outcomes were HIV incidence and
Herpes simplex virus type 2 (HSV2) in a cohort of 9,645 adolescents, mean age 15.5 years,
[95% range 14.1-18.3 years], who were recruited in late 1998 before entering Year 5, 6 or 7
of primary school. Secondary outcomes included six further biomedical, five behavioural, one
attitudinal, and three knowledge outcomes.
Findings: At the follow-up survey in late 2001-early 2002, the intervention had had a
statistically significant impact on all knowledge and attitudinal outcomes and also on
reported condom use and reported STI symptoms in both males and females. Significantly fewer
males in the intervention communities reported sexual debut during follow-up, or having
multiple sexual partners during the past 12 months, but no difference was seen for these two
outcomes among females. There were only five HIV seroconversions in males. Among females,
the adjusted rate ratio for HIV incidence (intervention vs comparison communities) was 0.76
(95%CI: 0.35,1.65). Overall prevalences of HSV2 were 11.9% in males and 21.1% in females,
with adjusted prevalence ratios (PRs) of 0.92 (95%CI:0.69,1.22) and 1.05 (95%CI:0.83,1.32)
respectively. There was no consistent impact on the other biological outcomes, with adjusted
PRs varying from 0.78 (95%CI:0.46,1.30) for syphilis in males to 1.94 (95%CI:1.01,3.72) for
gonorrhoea in females. A non-significant trend towards greater beneficial impact among
students enrolled in Year 4, who potentially received all three years of the in-school
programme, was seen for most outcomes. The beneficial impact on knowledge and reported
attitudes was confirmed in a cross-sectional survey in a different group of students who
were in Year 7 of primary school in mid-2002.
Conclusions: The intervention substantially improved knowledge, reported attitudes and
reported condom use in both sexes, and reported sexual behaviour in males, but had no
consistent impact on biological outcomes within the three-year trial period. The data
suggest a dose-related effect for several outcomes, with greater impact among those
receiving two or three years of the in-school programme.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |